Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + anlotinib + nab-paclitaxel for first-line treatment of recurrent/metastatic elderly cervical cancer
ChiCTR2500107702Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, anlotinib and paclitaxel in cervical cancer (mCC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-free survival (PFS). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
sintilimabanlotinibpaclitaxel
03
Conditions
cervical cancer (mCC)
Beyond the preview
Go deeper on ChiCTR2500107702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107702.